NCT07126561View on ClinicalTrials.gov

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2028

Study Completion Date

November 1, 2028

Conditions
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
Interventions
DRUG

Trastuzumab Deruxtecan

Do not substitute trastuzumab deruxtecan with trastuzumab or ado-trastuzumab emtansine. Do not administer as an intravenous push or bolus. Trastuzumab deruxtecan is not compatible with sodium chloride 0.9% solution for infusion. During treatment, patients should be observed for infusion-related reactions (IRRs). For additional information on the management of IRRs

All Listed Sponsors
lead

University of Chicago

OTHER

NCT07126561 - Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers | Biotech Hunter | Biotech Hunter